Vorinostat

Treatment Description

Vorinostat is an HDAC inhibitor that is currently approved for use in treating cutaneous T cell lymphoma (CTCL). It is being studied for use in several other indications.

Participating Centers

There are 7 centers running trials with this treatment. Enter a location below to find the closest center.